NO20062336L - Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander - Google Patents

Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander

Info

Publication number
NO20062336L
NO20062336L NO20062336A NO20062336A NO20062336L NO 20062336 L NO20062336 L NO 20062336L NO 20062336 A NO20062336 A NO 20062336A NO 20062336 A NO20062336 A NO 20062336A NO 20062336 L NO20062336 L NO 20062336L
Authority
NO
Norway
Prior art keywords
sodium
treatment
combinations
active substances
pain conditions
Prior art date
Application number
NO20062336A
Other languages
English (en)
Other versions
NO335896B1 (no
Inventor
Istvan Szelenyi
Kay Brune
Mathias Locher
Robert Hermann
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of NO20062336L publication Critical patent/NO20062336L/no
Publication of NO335896B1 publication Critical patent/NO335896B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører farmasøytiske kombinasjoner av kaliumkanalåpnere og natriumkanalinhibitorer for behandling av smertefulle tilstander forbundet med forhøyet muskeltonus.
NO20062336A 2003-10-23 2006-05-23 Kombinasjoner av kaliumkanalåpneren flupirtin, og natriumkanalinhibitorer eller aktive substanser som påvirker natriumkanaler for behandling av smertetilstander NO335896B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10349729 2003-10-23
DE10359335A DE10359335A1 (de) 2003-10-23 2003-12-16 Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
PCT/EP2004/011718 WO2005039576A1 (de) 2003-10-23 2004-10-18 Kombinationen aus kaliumkanalöffnern und natriumkanalinhibitoren oder natriumkanal beeinflussenden wirkstoffen zur behandlung von schmerzzuständen

Publications (2)

Publication Number Publication Date
NO20062336L true NO20062336L (no) 2006-07-11
NO335896B1 NO335896B1 (no) 2015-03-16

Family

ID=34524051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062336A NO335896B1 (no) 2003-10-23 2006-05-23 Kombinasjoner av kaliumkanalåpneren flupirtin, og natriumkanalinhibitorer eller aktive substanser som påvirker natriumkanaler for behandling av smertetilstander

Country Status (18)

Country Link
EP (1) EP1677787B1 (no)
JP (1) JP4855941B2 (no)
CN (1) CN1871000B (no)
AU (1) AU2004283472B2 (no)
CA (1) CA2542434C (no)
CY (1) CY1113789T1 (no)
DE (1) DE10359335A1 (no)
DK (1) DK1677787T3 (no)
ES (1) ES2401146T3 (no)
HK (1) HK1096308A1 (no)
HR (1) HRP20130176T1 (no)
NO (1) NO335896B1 (no)
NZ (1) NZ546522A (no)
PL (1) PL1677787T3 (no)
PT (1) PT1677787E (no)
RU (1) RU2355395C2 (no)
SI (1) SI1677787T1 (no)
WO (1) WO2005039576A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
AT500999A1 (de) * 2004-11-11 2006-05-15 Sanochemia Pharmazeutika Ag Tolperison enthaltendes veterinärmedizinisches präparat zur oralen verabreichung bei der behandlung von säugetieren, wie hunden mit degenerativen, spinalen symptomen
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN104784409A (zh) * 2015-03-30 2015-07-22 曹仁俊 一种治疗截瘫神经痛的中药组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2000143510A (ja) * 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
SI1677787T1 (sl) 2013-04-30
CA2542434C (en) 2013-06-25
RU2355395C2 (ru) 2009-05-20
EP1677787A1 (de) 2006-07-12
CN1871000B (zh) 2010-06-09
EP1677787B1 (de) 2012-12-12
AU2004283472A1 (en) 2005-05-06
JP2007509100A (ja) 2007-04-12
CA2542434A1 (en) 2005-05-06
HRP20130176T1 (hr) 2013-03-31
WO2005039576A1 (de) 2005-05-06
PT1677787E (pt) 2013-03-07
NO335896B1 (no) 2015-03-16
HK1096308A1 (en) 2007-06-01
CN1871000A (zh) 2006-11-29
DK1677787T3 (da) 2013-03-18
AU2004283472B2 (en) 2010-02-11
CY1113789T1 (el) 2016-07-27
NZ546522A (en) 2009-09-25
JP4855941B2 (ja) 2012-01-18
PL1677787T3 (pl) 2013-05-31
DE10359335A1 (de) 2005-05-25
RU2006117525A (ru) 2007-12-10
ES2401146T3 (es) 2013-04-17

Similar Documents

Publication Publication Date Title
NO20062336L (no) Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MY169308A (en) Treatment of tnf? related disorders
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
NO20056161L (no) Formuleringer for behandling av artrittilstander
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
SI1937669T1 (sl) Novi derivati benzopirana kot odpiralci kalijevega kanala
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20071208L (no) Trisykliske 5-opioidmodulatorer
TW200509896A (en) Analeptic and drug combinations
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
MY136367A (en) Treatment of cognitive failure
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
DK1567139T3 (da) Hidtil ukendt synergistisk kombination der omfatter roflumilast og formoterol

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDA PHARMA GMBH & CO KG, DE

MM1K Lapsed by not paying the annual fees